Literature DB >> 31754005

Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.

Iván M Moya1,2, Stéphanie A Castaldo1, Laura Van den Mooter1, Soheil Soheily1, Leticia Sansores-Garcia1, Jelle Jacobs3, Inge Mannaerts4, Jun Xie1, Elisabeth Verboven1, Hanne Hillen1, Ana Algueró-Nadal1, Ruchan Karaman1, Matthias Van Haele5, Weronika Kowalczyk1, Maxime De Waegeneer3, Stefaan Verhulst4, Panagiotis Karras6, Leen van Huffel1, Lars Zender7,8,9, Jean-Christophe Marine6, Tania Roskams5, Randy Johnson10, Stein Aerts3, Leo A van Grunsven4, Georg Halder11.   

Abstract

The Hippo signaling pathway and its two downstream effectors, the YAP and TAZ transcriptional coactivators, are drivers of tumor growth in experimental models. Studying mouse models, we show that YAP and TAZ can also exert a tumor-suppressive function. We found that normal hepatocytes surrounding liver tumors displayed activation of YAP and TAZ and that deletion of Yap and Taz in these peritumoral hepatocytes accelerated tumor growth. Conversely, experimental hyperactivation of YAP in peritumoral hepatocytes triggered regression of primary liver tumors and melanoma-derived liver metastases. Furthermore, whereas tumor cells growing in wild-type livers required YAP and TAZ for their survival, those surrounded by Yap- and Taz-deficient hepatocytes were not dependent on YAP and TAZ. Tumor cell survival thus depends on the relative activity of YAP and TAZ in tumor cells and their surrounding tissue, suggesting that YAP and TAZ act through a mechanism of cell competition to eliminate tumor cells.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31754005     DOI: 10.1126/science.aaw9886

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  49 in total

Review 1.  Hippo-YAP signaling in digestive system tumors.

Authors:  Feng Yin; Jixin Dong; Liang-I Kang; Xiuli Liu
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 2.  Emerging mechanisms of cell competition.

Authors:  Nicholas E Baker
Journal:  Nat Rev Genet       Date:  2020-08-10       Impact factor: 53.242

Review 3.  Outcompeting cancer.

Authors:  Medhavi Vishwakarma; Eugenia Piddini
Journal:  Nat Rev Cancer       Date:  2020-01-13       Impact factor: 60.716

4.  An RGDKGE-Containing Cryptic Collagen Fragment Regulates Phosphorylation of Large Tumor Suppressor Kinase-1 and Controls Ovarian Tumor Growth by a Yes-Associated Protein-Dependent Mechanism.

Authors:  XiangHua Han; Jennifer M Caron; Christine W Lary; Pradeep Sathyanarayana; Calvin Vary; Peter C Brooks
Journal:  Am J Pathol       Date:  2020-12-08       Impact factor: 4.307

Review 5.  Mechanoregulation of YAP and TAZ in Cellular Homeostasis and Disease Progression.

Authors:  Xiaomin Cai; Kuei-Chun Wang; Zhipeng Meng
Journal:  Front Cell Dev Biol       Date:  2021-05-24

6.  Active elimination of intestinal cells drives oncogenic growth in organoids.

Authors:  Ana Krotenberg Garcia; Arianna Fumagalli; Huy Quang Le; Rene Jackstadt; Tamsin Rosemary Margaret Lannagan; Owen James Sansom; Jacco van Rheenen; Saskia Jacoba Elisabeth Suijkerbuijk
Journal:  Cell Rep       Date:  2021-07-06       Impact factor: 9.423

7.  Fascin1 empowers YAP mechanotransduction and promotes cholangiocarcinoma development.

Authors:  Arianna Pocaterra; Gloria Scattolin; Patrizia Romani; Cindy Ament; Silvia Ribback; Xin Chen; Matthias Evert; Diego F Calvisi; Sirio Dupont
Journal:  Commun Biol       Date:  2021-06-21

8.  Preliminary Study on the In Vitro Antitumor Effects of Nidus Vespae on Gastric Cancer.

Authors:  Ming Zhu; Weiwei Han; Yang Ling; Qiufeng Qi; Yaping Zhang; Yun Peng; Lin Chen; Yanqing Bao; Yongping Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-07       Impact factor: 2.629

9.  Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity.

Authors:  Joel D Pearson; Katherine Huang; Marek Pacal; Sean R McCurdy; Suying Lu; Arthur Aubry; Tao Yu; Kristine M Wadosky; Letian Zhang; Tao Wang; Alex Gregorieff; Mohammad Ahmad; Helen Dimaras; Ellen Langille; Susan P C Cole; Philippe P Monnier; Benjamin H Lok; Ming-Sound Tsao; Nagako Akeno; Daniel Schramek; Kathryn A Wikenheiser-Brokamp; Erik S Knudsen; Agnieszka K Witkiewicz; Jeffrey L Wrana; David W Goodrich; Rod Bremner
Journal:  Cancer Cell       Date:  2021-07-21       Impact factor: 31.743

10.  YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior.

Authors:  Youngsic Jeon; Jeong Eun Yoo; Hyungjin Rhee; Young-Joo Kim; Gwang Il Kim; Taek Chung; Sarah Yoon; Boram Shin; Hyun Goo Woo; Young Nyun Park
Journal:  Exp Mol Med       Date:  2021-06-18       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.